» Articles » PMID: 17176753

Mode of Action of Microbial Bioactive Metabolites

Overview
Publisher Springer
Specialty Microbiology
Date 2006 Dec 21
PMID 17176753
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Pathogenic microorganisms can be suppressed by cell wall destruction. Biosynthesis of peptidoglycans forming bacterial cell wall is interrupted by glycopeptides which inhibit polymerization of a disaccharide formed by N-acetylglucosamine and N-acetylmuramic acid, beta-lactams and their derivatives inhibit peptidoglycan cross-linking. Antibiotics inhibiting protein synthesis bind to different sites on the rRNA and interfere with the formation of the polypeptide chain. Tumor cells resistant to chemotherapeutic drugs overproduce proteins transporting the drugs out of cells; these proteins eliminate substances which inhibit transcription of transport proteins. Some antitumor drugs (anthracyclines, fluoroquinolones, acridines etc.) act at topoisomerases which irreversibly bind to DNA and inhibit DNA synthesis. Immunosuppressants affect various components of the immune system such as T-helper, T-effector cell function, antigen presentation and B-cell function. Antiparasitics--avermectins--bind to a receptor of this Gab-gated chlorine channel in the nerve fiber of nematodes and anthropodes, increasing the permeability of the membrane for chloride ions; the increased transport of chloride ions into the cell causes the death of the parasite. Ionophores dissolve in phospholipid bilayers and enormously increase their ionic permeability. Respiration inhibitors block the transport of electrons at several places of the respiratory chain. Rifamycin binds to the beta subunit of bacterial RNA polymerase, thereby blocking mRNA synthesis. Antiviral compounds inhibit the transcription of DNA by several mechnisms or by inhibition of viral entry into host cells.

Citing Articles

Conversion of banana peel into diverse valuable metabolites using an autochthonous Rhodotorula mucilaginosa strain.

Torres-Alvarez D, Leon-Buitimea A, Albalate-Ramirez A, Rivas-Garcia P, Hernandez-Nunez E, Morones-Ramirez J Microb Cell Fact. 2022; 21(1):96.

PMID: 35643468 PMC: 9148461. DOI: 10.1186/s12934-022-01834-0.


Improving the bioremediation technology of contaminated wastewater using biosurfactants produced by novel bacillus isolates.

Darwesh O, Mahmoud M, Barakat K, Abuellil A, Ahmad M Heliyon. 2022; 7(12):e08616.

PMID: 34988315 PMC: 8703238. DOI: 10.1016/j.heliyon.2021.e08616.


Detection of antibacterial-like activity on a silica surface: fluoroquinolones and their environmental metabolites.

Lewis G, Juhasz A, Smith E Environ Sci Pollut Res Int. 2012; 19(7):2795-801.

PMID: 22311580 DOI: 10.1007/s11356-012-0781-8.


Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.

Lewis G, Juhasz A, Smith E Environ Sci Pollut Res Int. 2012; 19(7):2697-707.

PMID: 22307896 DOI: 10.1007/s11356-012-0766-7.


The influence of Lactobacillus acidophilus-derived surfactants on staphylococcal adhesion and biofilm formation.

Walencka E, Rozalska S, Sadowska B, Rozalska B Folia Microbiol (Praha). 2008; 53(1):61-6.

PMID: 18481220 DOI: 10.1007/s12223-008-0009-y.


References
1.
Rohrer S, Berger-Bachi B . FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and beta-lactam resistance in gram-positive cocci. Antimicrob Agents Chemother. 2003; 47(3):837-46. PMC: 149326. DOI: 10.1128/AAC.47.3.837-846.2003. View

2.
Dey S, Ramachandra M, Pastan I, Gottesman M, Ambudkar S . Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997; 94(20):10594-9. PMC: 23414. DOI: 10.1073/pnas.94.20.10594. View

3.
Ogawa H, Yamashita Y, Katahira R, Chiba S, Iwasaki T, Ashizawa T . UCH9, a new antitumor antibiotic produced by Streptomyces: I. Producing organism, fermentation, isolation and biological activities. J Antibiot (Tokyo). 1998; 51(3):261-6. DOI: 10.7164/antibiotics.51.261. View

4.
Heep M, Beck D, Bayerdorffer E, Lehn N . Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999; 43(6):1497-9. PMC: 89306. DOI: 10.1128/AAC.43.6.1497. View

5.
Kotra L, Haddad J, Mobashery S . Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother. 2000; 44(12):3249-56. PMC: 90188. DOI: 10.1128/AAC.44.12.3249-3256.2000. View